Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 2
2005 5
2006 6
2007 11
2008 9
2009 14
2010 13
2011 21
2012 17
2013 24
2014 35
2015 22
2016 35
2017 34
2018 52
2019 45
2020 71
2021 89
2022 108
2023 69
2024 25

Text availability

Article attribute

Article type

Publication date

Search Results

622 results

Results by year

Filters applied: . Clear all
Page 1
Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss.
Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, Kassir R, Singhal R, Mahawar K, Ramnarain D. Pouwels S, et al. BMC Endocr Disord. 2022 Mar 14;22(1):63. doi: 10.1186/s12902-022-00980-1. BMC Endocr Disord. 2022. PMID: 35287643 Free PMC article. Review.
Given the increasing prevalence of diabetes and obesity worldwide, the deleterious effects of non-alcoholic fatty liver disease (NAFLD) are becoming a growing challenge for public health. ...This is normally seen on liver biopsy and can range fr …
Given the increasing prevalence of diabetes and obesity worldwide, the deleterious effects of non-alcoholic fatty liver …
Current treatment of non-alcoholic fatty liver disease.
Paternostro R, Trauner M. Paternostro R, et al. J Intern Med. 2022 Aug;292(2):190-204. doi: 10.1111/joim.13531. Epub 2022 Jul 7. J Intern Med. 2022. PMID: 35796150 Free PMC article. Review.
Non-alcoholic fatty liver disease (NAFLD) comprises a wide spectrum of pathologies ranging from non-alcoholic fatty liver (NAFL), characterized by simple steatosis without inflammation, to non-alcoholic steatohepatitis (NASH …
Non-alcoholic fatty liver disease (NAFLD) comprises a wide spectrum of pathologies ranging from non-alcoholic …
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD).
Rong L, Zou J, Ran W, Qi X, Chen Y, Cui H, Guo J. Rong L, et al. Front Endocrinol (Lausanne). 2023 Jan 16;13:1087260. doi: 10.3389/fendo.2022.1087260. eCollection 2022. Front Endocrinol (Lausanne). 2023. PMID: 36726464 Free PMC article. Review.
Non-alcoholic fatty liver disease (NAFLD) is a series of diseases, involving excessive lipid deposition in the liver and is often accompanied by obesity, diabetes, dyslipidemia, abnormal blood pressure, and other metabolic disorders. In order to …
Non-alcoholic fatty liver disease (NAFLD) is a series of diseases, involving excessive lipid deposition in the …
Current treatment paradigms and emerging therapies for NAFLD/NASH.
Raza S, Rajak S, Upadhyay A, Tewari A, Anthony Sinha R. Raza S, et al. Front Biosci (Landmark Ed). 2021 Jan 1;26(2):206-237. doi: 10.2741/4892. Front Biosci (Landmark Ed). 2021. PMID: 33049668 Free PMC article. Review.
Non-alcoholic fatty liver disease (NAFLD) is one the fastest emerging manifestations of the metabolic syndrome worldwide. ...Currently, there is no FDA approved therapy for this disease and appropriate therapeutic targets are urgen …
Non-alcoholic fatty liver disease (NAFLD) is one the fastest emerging manifestations of the metabolic syndrome w …
Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis and Natural Products for Prevention and Treatment.
Guo X, Yin X, Liu Z, Wang J. Guo X, et al. Int J Mol Sci. 2022 Dec 7;23(24):15489. doi: 10.3390/ijms232415489. Int J Mol Sci. 2022. PMID: 36555127 Free PMC article. Review.
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease, affecting approximately one-quarter of the global population, and has become a world public health issue. ...This paper reviews the pathogenesis of NAF …
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease, affecting a …
ESPEN practical guideline: Clinical nutrition in liver disease.
Bischoff SC, Bernal W, Dasarathy S, Merli M, Plank LD, Schütz T, Plauth M. Bischoff SC, et al. Clin Nutr. 2020 Dec;39(12):3533-3562. doi: 10.1016/j.clnu.2020.09.001. Epub 2020 Oct 27. Clin Nutr. 2020. PMID: 33213977
The guideline is dedicated to all professionals including physicians, dieticians, nutritionists and nurses working with patients with chronic liver disease. RESULTS: A total of 103 statements and recommendations are presented with short commentaries for the nutritio …
The guideline is dedicated to all professionals including physicians, dieticians, nutritionists and nurses working with patients with chroni …
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus.
Ferguson D, Finck BN. Ferguson D, et al. Nat Rev Endocrinol. 2021 Aug;17(8):484-495. doi: 10.1038/s41574-021-00507-z. Epub 2021 Jun 15. Nat Rev Endocrinol. 2021. PMID: 34131333 Free PMC article. Review.
Non-alcoholic fatty liver disease (NAFLD) has emerged as the most prevalent liver disease in the world, yet there are still no approved pharmacological therapies to prevent or treat this condition. ...Thus, targeting these intercon …
Non-alcoholic fatty liver disease (NAFLD) has emerged as the most prevalent liver disease in the w …
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH.
Tacke F, Puengel T, Loomba R, Friedman SL. Tacke F, et al. J Hepatol. 2023 Aug;79(2):552-566. doi: 10.1016/j.jhep.2023.03.038. Epub 2023 Apr 14. J Hepatol. 2023. PMID: 37061196 Review.
Successful development of treatments for non-alcoholic fatty liver disease and its progressive form, non-alcoholic steatohepatitis (NASH), has been challenging. ...Heterogeneity of disease - either due to genetics or divergent disease …
Successful development of treatments for non-alcoholic fatty liver disease and its progressive form, non-alco …
NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options.
Foerster F, Gairing SJ, Müller L, Galle PR. Foerster F, et al. J Hepatol. 2022 Feb;76(2):446-457. doi: 10.1016/j.jhep.2021.09.007. Epub 2021 Sep 20. J Hepatol. 2022. PMID: 34555422 Review.
In light of a global rise in obesity and type 2 diabetes, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) represent an increasingly important underlying aetiology of hepatocellular carcinoma (HCC). ...While loc …
In light of a global rise in obesity and type 2 diabetes, non-alcoholic fatty liver disease (NAFLD) and non-a …
ESPEN guideline on clinical nutrition in liver disease.
Plauth M, Bernal W, Dasarathy S, Merli M, Plank LD, Schütz T, Bischoff SC. Plauth M, et al. Clin Nutr. 2019 Apr;38(2):485-521. doi: 10.1016/j.clnu.2018.12.022. Epub 2019 Jan 16. Clin Nutr. 2019. PMID: 30712783 Free PMC article.
This update of evidence-based guidelines (GL) aims to translate current evidence and expert opinion into recommendations for multidisciplinary teams responsible for the optimal nutritional and metabolic management of adult patients with liver disease. The GL was com …
This update of evidence-based guidelines (GL) aims to translate current evidence and expert opinion into recommendations for multidisciplina …
622 results